Ying Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying Lv has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Yongchun Li
Department of the Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publications- Aiwu Li
NanFang Hospital, Guangzhou, 510515, China
1 shared publication Ciai Lai
Department 2nd Clinical Medical College, Organization Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publicationDandan Lou
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
1 shared publicationDaoqi Zhu
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
1 shared publicationFengying Gong
Department of Traditional Chinese Medicine, Nanfang Hospital of Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (9) , 2241-2258
Association between polyunsaturated fatty acid intake and allergic rhinitis in children and adolescents: a cross-sectional study of the 2007–2016 NHANES data
Background: Allergic rhinitis (AR) is a prevalent immune-mediated disease, increasingly affecting children and adolescents. While diet is suspected to influence allergic diseases, the link between polyunsaturated fatty acids [PUFAs; omega-3 (n-3), and omega-6 (n-6)] and AR, particularly in younger populations, remains unclear. The gut microbiota’s role as a potential modifier also warrants investigation. This study aims to assess the correlation between dietary PUFA intake and AR status and explore the potential involvement of gut microbiota characteristics. Methods: This cross-sectional study analyzed data from the 2007–2016 National Health and Nutrition Examination Survey (NHANES), including 994 children and adolescents (1–16 years). Dietary PUFA intake [total PUFAs (TPFAs), n-3, and n-6] was assessed using 2-day 24-hour dietary recalls. AR status was determined by self-reported physician diagnosis and symptoms in the past year. Covariates, including demographics, clinical conditions, and dietary components, were adjusted for. Gut microbiota data were obtained from an external cohort involving 16S ribosomal RNA (rRNA) sequencing of fecal samples from 24 AR patients and 25 healthy controls, focusing on the V3–V4 region. Generalized linear mixed-effects models were used to evaluate associations between PUFA intake and AR, accounting for random effects and key interactions. Results: The study included 994 participants (mean age 9 years; 46.4% male). TPFA intake was significantly associated with an increased risk of AR [odds ratio (OR) =1.02; 95% confidence interval (CI): 1.00–1.04; P=0.03]. Specifically, n-6 PUFA intake was positively associated with AR risk (OR =1.02; 95% CI: 1.00–1.04; P=0.03), with octadecadienoic acid/18:2 (OR =1.02; 95% CI: 1.01–1.03; P=0.03) and octadecatrienoic acid (OR =1.23; 95% CI: 1.02–1.49; P=0.03) showing significant effects. No significant association was found between total n-3 intake and AR. The gut microbiome in AR patients showed a higher Firmicutes/Bacteroidetes (F/B) ratio and altered abundance of specific bacteria compared to healthy controls. Conclusions: Higher n-6 PUFA intake is associated with an increased risk of AR in children and adolescents and may contribute to gut microbiota dysbiosis, characterized by an elevated F/B ratio and reduced abundance of beneficial short-chain fatty acid (SCFA)-producing bacteria. N-3 PUFAs may help alleviate AR symptoms by modulating gut microbial composition and promoting anti-inflammatory responses. Dietary interventions optimizing the n-6/n-3 PUFA ratio and strategies to restore gut microbiota balance could offer potential avenues for AR prevention and management. Further research is needed to clarify causal relationships and underlying mechanisms involving PUFA intake, gut microbiota, and immune regulation in AR.
- 1 September 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (9) , 2241-2258
Open AccessAssociation between polyunsaturated fatty acid intake and allergic rhinitis in children and adolescents: a cross-sectional study of the 2007–2016 NHANES data
Background: Allergic rhinitis (AR) is a prevalent immune-mediated disease, increasingly affecting children and adolescents. While diet is suspected to influence allergic diseases, the link between polyunsaturated fatty acids [PUFAs; omega-3 (n-3), and omega-6 (n-6)] and AR, particularly in younger populations, remains unclear. The gut microbiota’s role as a potential modifier also warrants investigation. This study aims to assess the correlation between dietary PUFA intake and AR status and explore the potential involvement of gut microbiota characteristics. Methods: This cross-sectional study analyzed data from the 2007–2016 National Health and Nutrition Examination Survey (NHANES), including 994 children and adolescents (1–16 years). Dietary PUFA intake [total PUFAs (TPFAs), n-3, and n-6] was assessed using 2-day 24-hour dietary recalls. AR status was determined by self-reported physician diagnosis and symptoms in the past year. Covariates, including demographics, clinical conditions, and dietary components, were adjusted for. Gut microbiota data were obtained from an external cohort involving 16S ribosomal RNA (rRNA) sequencing of fecal samples from 24 AR patients and 25 healthy controls, focusing on the V3–V4 region. Generalized linear mixed-effects models were used to evaluate associations between PUFA intake and AR, accounting for random effects and key interactions. Results: The study included 994 participants (mean age 9 years; 46.4% male). TPFA intake was significantly associated with an increased risk of AR [odds ratio (OR) =1.02; 95% confidence interval (CI): 1.00–1.04; P=0.03]. Specifically, n-6 PUFA intake was positively associated with AR risk (OR =1.02; 95% CI: 1.00–1.04; P=0.03), with octadecadienoic acid/18:2 (OR =1.02; 95% CI: 1.01–1.03; P=0.03) and octadecatrienoic acid (OR =1.23; 95% CI: 1.02–1.49; P=0.03) showing significant effects. No significant association was found between total n-3 intake and AR. The gut microbiome in AR patients showed a higher Firmicutes/Bacteroidetes (F/B) ratio and altered abundance of specific bacteria compared to healthy controls. Conclusions: Higher n-6 PUFA intake is associated with an increased risk of AR in children and adolescents and may contribute to gut microbiota dysbiosis, characterized by an elevated F/B ratio and reduced abundance of beneficial short-chain fatty acid (SCFA)-producing bacteria. N-3 PUFAs may help alleviate AR symptoms by modulating gut microbial composition and promoting anti-inflammatory responses. Dietary interventions optimizing the n-6/n-3 PUFA ratio and strategies to restore gut microbiota balance could offer potential avenues for AR prevention and management. Further research is needed to clarify causal relationships and underlying mechanisms involving PUFA intake, gut microbiota, and immune regulation in AR.
- Open Access
- 26 July 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11, 1120728
Questionnaire-based analysis of autism spectrum disorders and gastrointestinal symptoms in children and adolescents: a systematic review and meta-analysis
Background: Gastrointestinal (GI) symptoms are frequently experienced by children with autism spectrum disorder (ASD), and these symptoms cause difficulties for these children and their families. However, studies of GI symptom prevalence differ significantly. This meta-analysis aimed to analyze the prevalence of GI symptoms in children with ASD.Methods and findings: PubMed, Scopus, Web of Science, EMBASE were electronically searched to collect all literature on gastrointestinal symptoms of children with ASD collected through questionnaires or scales from January 2012 to May 2021. Four researchers independently scanned the literature and extracted information on general characteristics. First author name, year of publication, geographical location, type of study, sample sizes of ASD and control (if any) children, sex and average age, number of GI cases, number of GI symptoms, GI assessment tools (gastrointestinal symptoms scale), autism diagnosis methods, and other necessary data were collected and analyzed using Stata V16. The questionnaires included the Rome, 6-GSI, GIQ, GSRS, GSIQ, ADI-R, PedsQL-GI, parent-report, GI-related, and self-administered questionnaires. Compared with typically developing (TD) children, the odds ratio for In children with ASD with at least one GI symptom was 3.64, and the total prevalence was 55%. The cumulative prevalence rates of various symptoms were summarized, showing that 37% of children with ASD had constipation, 21% had abdominal pain, 19% had diarrhea, 8% had vomiting, and 23% had abdominal distension.Conclusions: The results of this meta-analysis on GI symptoms in ASD show that patients with ASD are more likely to develop symptoms than TD children. The prevalence of GI symptoms in In children with ASD was 55%.Systematic Review Registration: www.crd.york.ac.uk/PROSPERO, identifier, #CRD42017080579.
- 26 July 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11, 1120728
Open AccessQuestionnaire-based analysis of autism spectrum disorders and gastrointestinal symptoms in children and adolescents: a systematic review and meta-analysis
Background: Gastrointestinal (GI) symptoms are frequently experienced by children with autism spectrum disorder (ASD), and these symptoms cause difficulties for these children and their families. However, studies of GI symptom prevalence differ significantly. This meta-analysis aimed to analyze the prevalence of GI symptoms in children with ASD.Methods and findings: PubMed, Scopus, Web of Science, EMBASE were electronically searched to collect all literature on gastrointestinal symptoms of children with ASD collected through questionnaires or scales from January 2012 to May 2021. Four researchers independently scanned the literature and extracted information on general characteristics. First author name, year of publication, geographical location, type of study, sample sizes of ASD and control (if any) children, sex and average age, number of GI cases, number of GI symptoms, GI assessment tools (gastrointestinal symptoms scale), autism diagnosis methods, and other necessary data were collected and analyzed using Stata V16. The questionnaires included the Rome, 6-GSI, GIQ, GSRS, GSIQ, ADI-R, PedsQL-GI, parent-report, GI-related, and self-administered questionnaires. Compared with typically developing (TD) children, the odds ratio for In children with ASD with at least one GI symptom was 3.64, and the total prevalence was 55%. The cumulative prevalence rates of various symptoms were summarized, showing that 37% of children with ASD had constipation, 21% had abdominal pain, 19% had diarrhea, 8% had vomiting, and 23% had abdominal distension.Conclusions: The results of this meta-analysis on GI symptoms in ASD show that patients with ASD are more likely to develop symptoms than TD children. The prevalence of GI symptoms in In children with ASD was 55%.Systematic Review Registration: www.crd.york.ac.uk/PROSPERO, identifier, #CRD42017080579.
- Open Access
- 7 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 976561
Astragalus Mongholicus: A review of its anti-fibrosis properties
Background: Fibrosis-related diseases (FRD) include cerebral fibrosis, pulmonary fibrosis, cardiac fibrosis, liver fibrosis, renal fibrosis, peritoneal fibrosis, etc. The effects of fibrosis can be severe, resulting in organ dysfunction, functional decline, and even organ failure, which can cause serious health problems.Aim: Currently, there is no effective modern medicine for anti-fibrosis in the clinics; however, Chinese medicine has a certain beneficial effect on treating such diseases. Astragalus Mongholicus (AM) has rich medicinal value, and its anti-fibrosis effect has been recently investigated. In recent years, more and more experimental studies have been conducted on the intervention of astragaloside IV (AS-IV), astragalus polysaccharide (APS), astragalus flavone, cycloastragalus alcohol, astragalus water extract and other pharmacological components in fibrosis-related diseases, attracting the interest of researchers. We aim to provide ideas for future research by summarizing recent research advances of AM in treating fibrosis-related diseases.Methods: A literature search was conducted from the core collections of electronic databases such as Baidu Literature, Sciencen.com, Google Scholar, PubMed, and Science Direct using the above keywords and the pharmacological and phytochemical details of the plant.Results: AM can be used to intervene in fibrosis-disease progression by regulating inflammation, oxidative stress, the immune system, and metabolism.Conclusion: AS-IV, APS, and astragalus flavone were studied and discussed in detail. These components have high potential anti-fibrosis activity. Overall, this review aims to gain insight into the AM’s role in treating fibro-related diseases.
- 7 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 976561
Open AccessAstragalus Mongholicus: A review of its anti-fibrosis properties
Background: Fibrosis-related diseases (FRD) include cerebral fibrosis, pulmonary fibrosis, cardiac fibrosis, liver fibrosis, renal fibrosis, peritoneal fibrosis, etc. The effects of fibrosis can be severe, resulting in organ dysfunction, functional decline, and even organ failure, which can cause serious health problems.Aim: Currently, there is no effective modern medicine for anti-fibrosis in the clinics; however, Chinese medicine has a certain beneficial effect on treating such diseases. Astragalus Mongholicus (AM) has rich medicinal value, and its anti-fibrosis effect has been recently investigated. In recent years, more and more experimental studies have been conducted on the intervention of astragaloside IV (AS-IV), astragalus polysaccharide (APS), astragalus flavone, cycloastragalus alcohol, astragalus water extract and other pharmacological components in fibrosis-related diseases, attracting the interest of researchers. We aim to provide ideas for future research by summarizing recent research advances of AM in treating fibrosis-related diseases.Methods: A literature search was conducted from the core collections of electronic databases such as Baidu Literature, Sciencen.com, Google Scholar, PubMed, and Science Direct using the above keywords and the pharmacological and phytochemical details of the plant.Results: AM can be used to intervene in fibrosis-disease progression by regulating inflammation, oxidative stress, the immune system, and metabolism.Conclusion: AS-IV, APS, and astragalus flavone were studied and discussed in detail. These components have high potential anti-fibrosis activity. Overall, this review aims to gain insight into the AM’s role in treating fibro-related diseases.
- Open Access
- 2 December 2020
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 11 (6) , 783-790
Effect of Shengmai Yin on the DNA methylation status of nasopharyngeal carcinoma cell and its radioresistant strains
- 2 December 2020
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 11 (6) , 783-790
Open AccessEffect of Shengmai Yin on the DNA methylation status of nasopharyngeal carcinoma cell and its radioresistant strains